The tumor immune microenvironment remodeling and response to HER2 ‐targeted therapy in HER2 ‐positive advanced gastric cancer
IUBMB Life · 2024-07 · 76 (7) · 420-436
DOI: 10.1002/iub.2804 ↗Kurz gefasst
Fachartikel in der Zeitschrift IUBMB Life, online erschienen am 21.12.2023. Verfasst von Lei Jiang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking Universi…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Stomach Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: Beijing Hospitals Authority Youth Programme, Beijing Municipal Natural Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Combination therapy with anti‐HER2 agents and immunotherapy has demonstrated significant clinical benefits in gastric cancer (GC), but the underlying mechanism remains unclear. In this study, we used multiplex immunohistochemistry to assess the changes of the tumor microenvironment in 47 advanced GC patients receiving anti‐HER2 therapy. Additionally, we performed single‐cell transcriptional sequencing to investigate potential cell‐to‐cell communication and molecular mechanisms in four HER2‐positive GC baseline samples. We observed that post‐treated the infiltration of NK cells, CD8 + T cells, and B lymphocytes were significantly higher in patients who benefited from anti‐HER2 treatment than baseline. Further spatial distribution analysis demonstrated that the interaction scores between NK cells and CD8 + T cells, B lymphocytes and M2 macrophages, B lymphocytes and Tregs were also significantly higher in benefited patients. Cell–cell communication analysis from scRNA sequencing showed that NK cells utilized CCL3/CCL4‐CCR5 to recruit CD8 + T cell infiltration. B lymphocytes employed CD74‐APP/COPA/MIF to interact with M2 macrophages, and utilized TNF‐FAS/ICOS/TNFRSR1B to interact with Tregs. These cell–cell interactions contribute to inhibit the immune resistance of M2 macrophages and Tregs. Our research provides potential guidance for the use of anti‐HER2 therapy in combination with immune therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
- Key Laboratory of Precision Nutrition and Food Quality, Department of Nutrition and Health, China Agricultural University, Beijing, China.
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, China.
ORCID-Profile: Lei Jiang, Shengde Liu, Zizhen Zhang, Lin Shen
Förderung
- Beijing Hospitals Authority Youth Programme
- Beijing Municipal Natural Science Foundation
- National Natural Science Foundation of China
- Wu Jieping Medical Foundation
Zitieren
APA
Jiang, L., Zhao, X., Li, Y., Hu, Y., Sun, Y., Liu, S., Zhang, Z., Li, Y., Feng, X., Yuan, J., Li, J., Zhang, X., Chen, Y., & Shen, L. (2024). The tumor immune microenvironment remodeling and response to HER2 ‐targeted therapy in HER2 ‐positive advanced gastric cancer. IUBMB Life, 76(7), 420-436. https://doi.org/10.1002/iub.2804
Vancouver
Jiang L, Zhao X, Li Y, Hu Y, Sun Y, Liu S, et al. The tumor immune microenvironment remodeling and response to HER2 ‐targeted therapy in HER2 ‐positive advanced gastric cancer. IUBMB Life. 2024;76(7):420-436. doi:10.1002/iub.2804
BibTeX
@article{Jiang2024,
author = {Jiang, Lei and Zhao, Xingwang and Li, Yilin and Hu, Yajie and Sun, Yu and Liu, Shengde and Zhang, Zizhen and Li, Yanyan and Feng, Xujiao and Yuan, Jiajia and Li, Jian and Zhang, Xiaotian and Chen, Yang and Shen, Lin},
title = {The tumor immune microenvironment remodeling and response to HER2 ‐targeted therapy in HER2 ‐positive advanced gastric cancer},
journal = {IUBMB Life},
year = {2024},
volume = {76},
number = {7},
pages = {420--436},
doi = {10.1002/iub.2804}
}
EUVIMED